In particular, preliminary results from a phase 3 study in patients with advanced NSCLC have suggested that improved efficacy can be achieved when combining a VEGF inhibitor with a chemotherapy regimen that includes gemcitabine and cisplatin (Manegold et al, 2005). This evidence concerns the gene VEGFA and non-small cell lung carcinoma.